Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome

Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor–β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β–neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

[1]  J. Dudgeon.  Teratology. , 1986, Clinics of Perinatology.

[2]  R. Chen,et al.  Role of Angiotensin II–Regulated Apoptosis Through Distinct AT1 and AT2 Receptors in Neointimal Formation , 2002, Circulation.

[3]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[4]  Kevin B. Jones,et al.  Toward an Understanding of Dural Ectasia: A Light Microscopy Study in a Murine Model of Marfan Syndrome , 2005, Spine.

[5]  Richard P Visconti,et al.  Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[6]  AC Tose.  Cell , 1993, Cell.

[7]  D. Rifkin,et al.  Latent Transforming Growth Factor β-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein* , 2003, The Journal of Biological Chemistry.

[8]  A. Wear.  CIRCULATION , 1964, The Lancet.

[9]  N. Yorioka,et al.  Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1 , 2004 .

[10]  S. Topouzis,et al.  Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. , 1996, Developmental biology.

[11]  M. Sporn,et al.  A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β , 1988, Cell.

[12]  J O Barentsz,et al.  Pulmonary artery root dilatation in Marfan syndrome: quantitative assessment of an unknown criterion , 2002, Heart.

[13]  G. Wolf,et al.  Angiotensin II stimulates expression of transforming growth factor β receptor type II in cultured mouse proximal tubular cells , 1999, Journal of Molecular Medicine.

[14]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[15]  N. Fukuda,et al.  Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells. , 2000, American journal of hypertension.

[16]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[17]  R. Derynck,et al.  Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Black,et al.  Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. , 2004, Journal of molecular and cellular cardiology.

[19]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[20]  J. Egido,et al.  Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005, Circulation.

[21]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[22]  A. Daugherty,et al.  Antagonism of AT2 receptors augments Angiotensin II‐induced abdominal aortic aneurysms and atherosclerosis , 2001, British journal of pharmacology.

[23]  S. Ledbetter,et al.  Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats , 2005, Journal of hypertension.

[24]  J. Coselli,et al.  Replacement of the aortic root in patients with Marfan's syndrome. , 1999, The New England journal of medicine.

[25]  A. Everett,et al.  Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. , 1994, Hypertension.

[26]  Jessica Geubtner,et al.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.

[27]  M. Entman,et al.  Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[28]  H. Robenek,et al.  Collagen synthesis in cultured aortic smooth muscle cells. Modulation by collagen lattice culture, transforming growth factor-beta 1, and epidermal growth factor. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[30]  R. Robertson,et al.  Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. , 1995, Teratology.

[31]  R. Glanville,et al.  Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. , 1991, The Journal of biological chemistry.

[32]  M. Dalton,et al.  Differential Response of Mesoderm- and Neural Crest-Derived Smooth Muscle to TGF-β1: Regulation of c-myb and α1 (I) Procollagen Genes , 1997 .